AbbVie says Phase 3 INTREPID study of lutikizumab met primary endpoint in hidradenitis suppurativa

AbbVie reported topline results from the Phase 3 INTREPID study of lutikizumab, an investigational dual-variable-domain IL-1α/1β antagonist, in hidradenitis suppurativa. The study met its primary endpoint and 8 ranked secondary endpoints.

Detected & updated continuously · Source: Nebula